Cerevance

Neurons in Parkinson's disease

First-in-class non-dopamine Parkinson’s therapy enters Phase II

20 November 2023

Cerevance has dosed the first patient in its ASCEND Phase II study to assess the efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease. In February 2023 the company expanded its Series B funding round, raising a total of $116 million.  “We are delighted to announce the commencement of our ASCEND study […]

""

$116 million financing will support neurological disease trials

15 February 2023

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel […]